Back to News
Market Impact: 0.25
InflaRx N.V. Reports €18.7 million Net Loss for the Nine Months Ended September 30, 2026
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
InflaRx reported a net loss of €18.7 million for the nine months ended September 30, 2026, and no revenue for the period. The company attributed the absence of revenue to the discontinuation of sales activities for GOHIBIC (vilobelimab).
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
IFRX-0.45
More News
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- AMD rides data center riches to ‘largest and most profitable’ quarter in history
- AMD’s OpenAI, Meta chip deals trigger $1 billion quarterly charge